chronic renal insufficiency

Overview

Chronic renal insufficiency is a clinical term used for long-standing, progressive loss of kidney function. In contemporary biomedical literature, it is often used interchangeably with chronic kidney disease (CKD) or chronic renal failure, although CKD is the preferred modern term. The condition is characterized by persistent structural or functional kidney impairment, reduced glomerular filtration rate, albuminuria, and progressive tubulointerstitial fibrosis. Over time, chronic renal insufficiency can lead to complications such as anemia, hypertension, cardiovascular disease, mineral and bone disorders, metabolic dysregulation, and eventual end-stage kidney failure.

Biologically, chronic renal insufficiency reflects a final common pathway of diverse kidney injuries, including diabetic nephropathy, ischemic injury, immune-mediated disease, and age-related decline. Recent research emphasizes mechanisms such as transforming growth factor-beta signaling, MAPK pathways, oxidative stress, mitochondrial dysfunction, cellular senescence, podocyte injury, and renal fibrosis. Because it is tightly linked to type 2 diabetes, heart failure, cardiovascular disease, and systemic inflammation, chronic renal insufficiency is also a major target for cardio-kidney-metabolic therapies, including sodium-glucose cotransporter-2 (SGLT2) inhibitors, finerenone, and prolyl hydroxylase inhibitors.

Focus of Latest Publications

Recent studies have treated chronic renal insufficiency primarily as a progressive disease state, a risk modifier for other clinical outcomes, and a therapeutic target. Several papers focused on CKD progression and fibrosis, describing chronic kidney disease as a condition driven by renal fibrosis, podocyte injury, mitochondrial damage, and tubulointerstitial remodeling. One medicinal chemistry study designed potent, selective, peripherally acting JNK3 inhibitors for chronic kidney disease, based on the concept that CKD is characterized by progressive fibrosis and podocyte injury driven in part by TGF-β-dependent MAPK signaling. Another multi-omics study reported that burdock seed aglycone alleviated renal fibrosis by restoring mitochondrial oxidative phosphorylation function, reinforcing the central role of mitochondrial dysfunction in chronic renal insufficiency. Similarly, studies on DYRK1A/FOXO1 signaling, CaMKIIδ expression, and mitophagy-related pathways linked cellular senescence, lipid accumulation, and fibrosis severity to CKD pathology.

A substantial portion of the recent literature examined chronic renal insufficiency in the context of diabetes and cardio-renal risk. SGLT2 inhibitors were evaluated both for prevention of incident CKD in type 2 diabetes and as cornerstone therapies recommended for patients with CKD, heart failure, or atherosclerotic cardiovascular disease. finerenone was also highlighted as a renoprotective therapy, with studies assessing its effects in CKD associated with type 2 diabetes, including patients with a history of nephrectomy and those with different pre-treatment eGFR trajectories. A separate trial program, TRANSCEND-CKD, was designed to test retatrutide in patients with chronic kidney disease, reflecting interest in metabolic therapies that may influence kidney disease pathways. In type 1 diabetes, finerenone was specifically studied for efficacy and safety in persons with CKD, underscoring the expansion of mineralocorticoid receptor antagonism into broader CKD populations.

Other studies addressed complications and prognostic consequences of chronic renal insufficiency. CKD was associated with higher perioperative morbidity in surgical settings, including postoperative acute kidney injury in patients with pre-existing CKD and adverse perioperative outcomes after TURBT. In transplant-related and post-acute injury settings, CKD was described as a downstream consequence of acute kidney injury, hematopoietic stem cell transplantation conditioning, or liver transplantation. Chronic renal insufficiency also appeared in studies of cardiovascular and hematologic risk, including platelet activation and thrombosis, fracture risk, mortality risk, and susceptibility to cardiovascular complications in patients receiving renal anemia therapies such as roxadustat and daprodustat. In addition, CKD was linked to systemic inflammation, fatigue, sarcopenia-related pathways, and chronic pain syndromes such as fibromyalgia in hemodialysis patients.

Several publications focused on biomarkers, prediction, and staging. Renalase was investigated as a peptide biomarker in chronic kidney disease, with emphasis on assay-dependent variability in quantification. KIM-1 was used in a serum-based early warning approach combining surface-enhanced Raman spectroscopy and artificial intelligence for early diagnosis of CKD. Other work explored urinary fluorogenic reporters for noninvasive detection and staging of kidney fibrosis, targeted LC-MS/MS health surveillance panels, and machine learning models for forecasting incident CKD and postoperative AKI in CKD patients. These studies collectively suggest a strong research trend toward earlier detection, risk stratification, and individualized prediction of chronic renal insufficiency progression.

Chronic renal insufficiency was also studied in relation to systemic comorbidity and population health. obesity-related phenotypes, body roundness index, triglyceride-to-HDL cholesterol ratio, TyG index, and physical activity were all examined as risk or prognostic markers. Gut microbiome dysbiosis, maternal obesity, maternal protein restriction, aging, and metabolic syndrome were also implicated in CKD susceptibility or progression. Across these studies, chronic renal insufficiency was consistently framed as a global health burden affecting hundreds of millions of people and intersecting with diabetes, cardiovascular disease, and aging biology.

Key Publications

• Jun Can sodium-glucose cotransporter 2 (SGLT2) inhibition preserve renal structure and function in de novo kidney transplant recipients? Protocol for a randomised, double-blind, placebo-controlled trial assessing the efficacy of dapagliflozin on kidney structure, function and safety in kidney transplant recipients in Norway-the DEAK study. (BMJ open, 2026, PMID 42315275): "Recent studies have shown that sodium-glucose cotransporter 2 (SGLT2) inhibitors slow the progression of chronic kidney disease in people at high cardiovascular risk, with or without type 2 diabetes."
• Jun Unfavorable lifestyle, hypertriglyceridemia and smoking are risk factors for chronic kidney disease in people with type 2 diabetes. (Nutricion hospitalaria, 2026, PMID 41878915): "chronic kidney disease (CKD) is a major microvascular complication of type 2 diabetes."
• Jun Proteomic Mendelian randomization and machine learning reveal causal plasma biomarkers in cardiorenal comorbidity. (Renal failure, 2026, PMID 42299131): "Chronic kidney disease (CKD) significantly increases the risk of coronary artery disease (CAD), but the causal plasma proteins linking these conditions are poorly understood."
• Jun Integration of AHRR methylation, heavy metals, and clinical characteristics for urothelial carcinoma risk stratification: An explainable artificial intelligence approach. (Environmental pollution (Barking, Essex : 1987), 2026, PMID 42031200): "SHAP analysis identified chronic kidney disease and age as primary determinants, while AHRR methylation and selected metals (Ni, Cr) contributed significant independent discriminative value."
• Jun Systemic mesenchymal stem cell therapy for reduction of inflammatory burden in a patient with juvenile-onset rheumatoid arthritis and dialysis-dependent renal failure. (Croatian medical journal, 2026, PMID 42286909): "Chronic systemic inflammation is a key driver of disease progression in rheumatoid arthritis and chronic kidney disease (CKD), particularly in patients undergoing long-term hemodialysis."
• Jun Multi-omics reveals that burdock seed aglycone alleviates renal fibrosis by restoring mitochondrial oxidative phosphorylation function. (Journal of proteomics, 2026, PMID 42276167): "Renal fibrosis (RF), a common pathological process driving chronic kidney disease (CKD) progression to end-stage renal failure, is closely associated with oxidative phosphorylation (OXPHOS)."
• Jun QingShen granules activates mitophagy to suppress renal tubular epithelial-mesenchymal transition via the miR-23b-5p/Nrf2/PINK1 axis. (Journal of ethnopharmacology, 2026, PMID 41794259): "Renal fibrosis (RF) is a pivotal pathological process in chronic kidney disease (CKD), driven by tubular epithelial-mesenchymal transition (EMT)."
• Jun Impact of CKD on perioperative outcomes following TURBT: a national NSQIP analysis. (World journal of urology, 2026, PMID 42249173): "However, chronic kidney disease (CKD) is common in this population and may increase perioperative morbidity."
• Jun Design and optimization of potent, selective, and peripherally acting JNK3 inhibitors for chronic kidney disease. (European journal of medicinal chemistry, 2026, PMID 41880834): "Chronic kidney disease (CKD) is characterized by progressive fibrosis and podocyte injury driven in part by TGF-β-dependent MAPK signaling."
• Jun Prolyl hydroxylase inhibitors, roxadustat and daprodustat, inhibit platelet activation and thrombosis through the PI3K/AKT/HIF-1α pathway. (Biochemical pharmacology, 2026, PMID 41690412): "As innovative therapies for renal anemia, roxadustat and daprodustat are specifically indicated for populations with chronic kidney disease (CKD) who exhibit a significantly higher susceptibility to cardiovascular complications."